Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/103835
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pessoa, Bernardete | - |
dc.contributor.author | Malheiro, Luísa | - |
dc.contributor.author | Carneiro, Inês | - |
dc.contributor.author | Monteiro, Sílvia | - |
dc.contributor.author | Coelho, João | - |
dc.contributor.author | Coelho, Constança | - |
dc.contributor.author | Figueira, João | - |
dc.contributor.author | Meireles, Angelina | - |
dc.contributor.author | Beirão, João Nuno Melo | - |
dc.date.accessioned | 2022-12-02T08:52:45Z | - |
dc.date.available | 2022-12-02T08:52:45Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 1177-5467 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/103835 | - |
dc.description.abstract | Aim: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab. Methods: Single-center retrospective comparative study of patients with DME unresponsive to intravitreal bevacizumab that was switched to ranibizumab or aflibercept. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were analysed prior to and 4 months after the switch. Ocular coherence tomography (OCT) biomarkers were also analysed. Results: Fifty-six eyes from 40 patients were included in the study, 33 eyes switched to ranibizumab and 23 to aflibercept. A significant median CFT decrease was observed in both groups (p<0.001), with no between-group differences. BCVA gain was only significant in the ranibizumab group (p<0.001). None of the pre-baseline or baseline parameters were associated with the response to ranibizumab or aflibercept. Conclusion: In persistent DME unresponsive to bevacizumab, both anatomical and functional improvements were observed with ranibizumab whereas aflibercept only showed an anatomical improvement. Clinicaltrials.gov NCT04018833. | pt |
dc.language.iso | eng | pt |
dc.publisher | Dove Medical Press | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | pt |
dc.subject | aflibercept | pt |
dc.subject | bevacizumab | pt |
dc.subject | diabetic macular edema | pt |
dc.subject | ranibizumab, refractory | pt |
dc.title | Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis | pt |
dc.type | article | - |
degois.publication.firstPage | 253 | pt |
degois.publication.lastPage | 260 | pt |
degois.publication.title | Clinical Ophthalmology | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.2147/OPTH.S280644 | pt |
degois.publication.volume | 15 | pt |
dc.date.embargo | 2021-01-01 | * |
uc.date.periodoEmbargo | 0 | pt |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
item.fulltext | Com Texto completo | - |
item.grantfulltext | open | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairetype | article | - |
crisitem.author.orcid | 0000-0002-3511-1515 | - |
Appears in Collections: | FMUC Medicina - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Intravitreal-ranibizumab-or-aflibercept-after-bevacizumab-in-diabetic-macular-edema-Exploratory-retrospective-analysis2021Clinical-OphthalmologyOpen-Access.pdf | 1.81 MB | Adobe PDF | View/Open |
Page view(s)
57
checked on May 15, 2024
Download(s)
47
checked on May 15, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License